What is the safest first‑line therapy for sinus congestion in a patient with hypertension?

Sinus Congestion Treatment in Hypertensive Patients

First-Line Recommendation

Intranasal corticosteroids (such as mometasone furoate or fluticasone) are the safest and most effective first-line therapy for sinus congestion in patients with hypertension. 1

---

Rationale for Intranasal Corticosteroids

• Intranasal corticosteroids are the most effective medication class for controlling nasal congestion and are not associated with systemic blood pressure elevation. 1
• These agents work by reducing nasal inflammation and edema without sympathomimetic effects, making them ideal for hypertensive patients. 1
• Intranasal corticosteroids should be considered for initial treatment without requiring a trial of other agents first, particularly in patients with hypertension. 1
• Research demonstrates that treating nasal congestion with intranasal steroids (mometasone furoate) actually decreases blood pressure in patients with allergic rhinitis—daytime systolic BP dropped from 120 to 117 mmHg (p=0.024) and diastolic BP from 73 to 71 mmHg (p=0.027). 2

---

Oral Decongestants: Use with Caution

Pseudoephedrine

• Oral decongestants like pseudoephedrine can be used but require monitoring in hypertensive patients. 1
• Meta-analysis shows pseudoephedrine causes a small increase in systolic blood pressure (0.99 mmHg; 95% CI, 0.08-1.90) and heart rate (2.83 beats/min), with no effect on diastolic pressure. 1
• Hypertensive patients should be monitored when using pseudoephedrine due to interindividual variation in blood pressure response, even though the average effect is modest. 1
• Pseudoephedrine is generally well tolerated by most patients with controlled hypertension. 1

Phenylephrine

• Oral phenylephrine is less effective than pseudoephedrine as a decongestant due to extensive gut metabolism, and its efficacy as an oral agent is not well established. 1
• Phenylephrine remains available over-the-counter without restrictions, unlike pseudoephedrine. 1

Important Precautions

• Oral α-adrenergic agonists should be used with caution in patients with arrhythmias, angina pectoris, coronary artery disease, cerebrovascular disease, and hyperthyroidism. 1
• These agents can raise intraocular pressure. 1
• Oral decongestants may cause insomnia, loss of appetite, irritability, and palpitations. 1

---

Topical Decongestants: Short-Term Use Only

• Topical decongestants (oxymetazoline, phenylephrine, xylometazoline) can be considered for short-term (≤3 days) or intermittent therapy. 1
• These agents are inappropriate for regular daily use due to the risk of rhinitis medicamentosa (rebound congestion). 1
• With regular daily use, some patients may develop rhinitis medicamentosa in as little as 3 days, while others may not show rebound congestion until 4-6 weeks. 1
• Topical decongestants are appropriate for acute bacterial or viral infections, exacerbations of allergic rhinitis, and eustachian tube dysfunction. 1
• Intranasal vasoconstrictors do not significantly increase blood pressure in normotensive patients, and a randomized controlled trial found no significant blood pressure changes with oxymetazoline, phenylephrine, or lidocaine with epinephrine compared to saline. 3

---

Treatment Algorithm

Step 1: Initial Therapy

• Start with intranasal corticosteroid (e.g., mometasone furoate 2 sprays per nostril once daily, or fluticasone propionate 2 sprays per nostril once daily). 1
• Instruct the patient to direct sprays away from the nasal septum to minimize local irritation and bleeding. 1

Step 2: If Inadequate Response After 2-4 Weeks

• Add oral pseudoephedrine 30-60 mg every 4-6 hours (maximum 240 mg/day) for short-term relief. 1
• Monitor blood pressure within 1-2 weeks after starting pseudoephedrine. 1

Step 3: For Acute Exacerbations

• Consider topical decongestant (oxymetazoline 0.05% 2 sprays per nostril twice daily) for maximum 3 days. 1
• Resume intranasal corticosteroid after discontinuing topical decongestant. 1

Step 4: If Allergic Rhinitis is Present

• Add oral second-generation antihistamine (e.g., loratadine 10 mg daily, cetirizine 10 mg daily). 1
• Intranasal antihistamines (azelastine) may be used as an alternative but can cause sedation in some patients. 1

---

Common Pitfalls to Avoid

• Do not use topical decongestants for more than 3 consecutive days to prevent rhinitis medicamentosa. 1
• Do not assume oral decongestants are contraindicated in hypertension—they can be used with monitoring, especially in patients with controlled hypertension. 1
• Do not use first-generation antihistamines (diphenhydramine, chlorpheniramine) as first-line agents due to sedation, performance impairment, and anticholinergic effects; second-generation antihistamines are preferred. 1
• Do not delay starting intranasal corticosteroids while waiting to see if decongestants work—intranasal steroids are more effective for sustained congestion relief. 1
• Do not use oral decongestants in patients with uncontrolled hypertension (≥160/100 mmHg) until blood pressure is better controlled. 1

---

Special Considerations

Monitoring Requirements

• Check blood pressure 1-2 weeks after initiating oral decongestants in hypertensive patients. 1
• Examine the nasal septum periodically when using intranasal corticosteroids to ensure no mucosal erosions are developing. 1

Pregnancy

• Caution is recommended for decongestant use during the first trimester due to reported fetal heart rate changes. 1

Elderly Patients

• Topical vasoconstrictors should be used with care in patients below age 1 year due to narrow therapeutic margins and increased risk of cardiovascular and CNS side effects. 1